Baby Born from Rare Abdominal Pregnancy Beats 1-in-a-Million Odds
A California mother, unaware she was pregnant, gave birth to a healthy baby boy from a rare abdominal pregnancy. Discover the incredible medical miracle that stunned doctors.
Category : Search result: abdominal obesity
U.S. Approves Pill Version of Popular Weight-Loss Drug
U.S. regulators have greenlit a pill version of a leading weight-loss medication, potentially broadening treatment options. Learn about the approval and its implications.
Lilly pill keeps weight off after injectable drugs in trial
New data shows Eli Lilly's oral weight-loss drug successfully maintains weight reduction after patients switch from injectable medications. A breakthrough for chronic obesity management.
Hims & Hers Acquires Livewell for Canadian Expansion
U.S. telehealth giant Hims & Hers acquires Canadian platform Livewell, positioning itself to launch generic semaglutide (Ozempic) in Canada as Novo Nordisk's patent lapses. The move targets a market where two-thirds of adults face weight-related health ch
Novo Nordisk to test obesity drug CagriSema in children
Novo Nordisk, maker of Wegovy, plans clinical trials for its experimental obesity medication CagriSema in overweight children and adolescents. Get the latest details on this significant development in pediatric health.
Belly Fat Linked to Dangerous Heart Changes in Men
New research reveals abdominal fat, particularly in men, is strongly linked to dangerous heart remodelling. Learn the risks and what the data means for Canadians.
WHO Backs GLP-1 Treatments for Obesity Epidemic
The World Health Organization has officially endorsed GLP-1 receptor agonist treatments, including drugs like Ozempic, as a key tool to tackle the global obesity epidemic. Learn what this means for public health.
Eli Lilly cuts price of obesity drug Zepbound
Pharmaceutical giant Eli Lilly has reduced the price of its obesity medication Zepbound to improve patient access. The move comes amid growing demand for GLP-1 drugs in Canada and globally.
Novo's obesity drug shows 14.5% weight loss in trial
Novo Nordisk's experimental obesity drug amycretin demonstrates significant weight loss results in mid-stage study, advancing to late-phase testing for diabetes patients.
Pfizer wins $10B obesity drug takeover battle
Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.
Trump's Plan to Slash Obesity Drug Prices
Former President Donald Trump unveils ambitious strategy to dramatically reduce costs of groundbreaking weight-loss medications, promising relief for millions struggling with obesity.
Trump Reveals Deal to Lower Obesity Drug Costs
Former President Donald Trump reveals groundbreaking agreement with pharmaceutical giant to make obesity drugs more affordable and accessible across the United States.
Trump Obesity Drug Deal Boosts Pharma Stocks
Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.
Eli Lilly's Weight Loss Drugs Spark Billion-Dollar Bidding War
Pharmaceutical giant Eli Lilly reports explosive growth driven by Mounjaro and Zepbound, creating intense investor competition and reshaping the obesity treatment landscape.
Weight-Loss Pill Race Revolutionizes Healthcare Market
Pharmaceutical giants and startups race to develop next-generation weight-loss treatments as demand soars and market valuations skyrocket in this healthcare revolution.
Hidden Obesity: Why Your BMI Might Be Lying
New Canadian research exposes the limitations of BMI, revealing millions with normal weight may have 'hidden obesity' and face serious health risks. Discover the silent epidemic your scale isn't showing you.
Page 1 of 1